Geron shares rise 13.14% after-hours after FDA designations and positive clinical trial results boost investor confidence.

Geron Corporation surged 13.14% in after-hours trading following two key developments: (1) TD Cowen analyst Tara Bancroft revised the price target for GERN from $4 to $3 while maintaining a "Buy" rating, citing FDA designations and promising clinical results for RYTELO, and (2) the company projected $220M–$240M in RYTELO revenue for fiscal 2026, alongside plans to expand U.S. market reach and advance its Phase 3 IMpactMF trial. The upward move reflects investor optimism around RYTELO’s growth potential, despite the analyst’s lower price target, which analysts attribute to strategic positioning for long-term gains. The stock’s post-market rally aligns with positive sentiment around clinical progress and revenue forecasts, which reinforce confidence in Geron’s ability to scale its flagship product amid competitive market dynamics.